Determining prognostic factors in the treatment of primary hemifacial spasm: Clinical outcomes and complications. A literature review by Juan Carlos Acevedo-González, Alex Taub-Krivoy, Julian Alfonso Sierra-Peña, Julian Geronimo Lizarazo

“…Each author reviewed abstracts, applying inclusion criteria like systematic reviews, clinical trials, observational studies, and case series, while excluding theoretical or non-English articles. …”
Get full text

Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

“…Here, we provide here a comprehensive review of cellular signaling pathways, their therapeutic potential, evidence derived from late-stage clinical trials in HCC and discuss the concepts underlying earlier clinical trials, biomarker identification, and the development of more effective therapeutics for HCC.…”
Get full text

Efficacy of the herbal preparation STW 5 in multi-target therapy of functional dyspepsia by A. A. Sheptulin, V. O. Kaybysheva

“…Mechanism of action includes effect on motility of the stomach and intestine, visceral sensitivity along with anti-inflammatory and cytoprotective effects. Controlled clinical trials have confirmed high efficacy of Iberogast® at treatment of FD (including pediatric practice) as well as good tolerability of the drug.Conclusion. …”
Get full text

A comprehensive review of remimazolam for sedation by Nazir Noor, Rhorer Legendre, Alexandra Cloutet, Ahish Chitneni, Giustino Varrassi, Alan D. Kaye

“…However, further large clinical trials will provide us with a better understanding of the advantages and disadvantages of remimazolam.…”
Get full text

From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases by Qing Zhao, Linxin Wei, Youxin Chen

“…This review summarizes the application strategies and delivery methods of CRISPR/Cas, discusses recent progress in CRISPR/Cas-based disease models and therapies, and provides an overview of the landscape of clinical trials. Current obstacles and future directions regarding the bench-to-bedside transition are also discussed.…”
Get full text

Improving drug repositioning with negative data labeling using large language models by Milan Picard, Mickael Leclercq, Antoine Bodein, Marie Pier Scott-Boyer, Olivier Perin, Arnaud Droit

“…Results We proposed a novel strategy using Large Language Models (GPT-4) to analyze all clinical trials on prostate cancer and systematically identify true negatives. …”
Get full text

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives by Dong Luo, Yunmei Liu, Zhengmao Lu, Lei Huang

“…Innovative immunotherapy modalities, including adoptive immune cell therapy, tumor vaccines, and non-specific immunomodulators therapy, and oncolytic viruses have shown promise in early-stage clinical trials for GC. Clinical trials have supported that targeted therapy and immunotherapy can significantly improve the survival and quality of life of GC patients. …”
Get full text

Non-pharmacological interventions for the reduction and maintenance of blood pressure in people with prehypertension: a systematic review protocol by Paul Rutter, Andrew Clegg, Valerio Benedetto, Caroline Watkins, Nefyn Williams, Joseph Spencer, Lucy Hives, Emma P Bray, Cath Harris, Rachel F Georgiou, Nafisa Iqbal

“…The databases/trial registries that will be searched to identify relevant randomised controlled trials (RCTs) and economic evaluations include Medline, EMBASE, CINAHL, PsycINFO, CENTRAL, the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, Cochrane Library, Scopus and the International HTA Database. …”
Get full text

Therapeutics in paediatric genetic diseases: current and future landscape by Ai Ling Koh, Saumya Shekhar Jamuar

“…Specifically, gene therapy has been shown to be effective in various clinical trials, and indeed, these trials have led to regulatory approvals, paving the way for gene therapies for other types of PGDs. …”
Get full text

“Lost in translation?” Animal research in the era of precision medicine by Hamideh Frühwein, Norbert W. Paul

“…Abstract Preclinical animal research has long been a cornerstone in evaluating the efficacy, toxicity, and safety of potential drug treatments before they proceed to human clinical trials. However, given the intricate nature of human physiology and the complexities of diseases such as cancer, this paper critically examines the role of animal experimentation in translational research, both from epistemological and ethical viewpoints. …”
Get full text

Erratum to ‘Efficacy and safety of local fibrinolytic therapy in intracranial hemorrhages: A systematic review and meta-analysis of randomised controlled trials’ [World Neurosurger... by Arun Babu Rajeswaran, Arshad Ali, Saleh Safi, Ahmed Eid Abdulghani Saleh

“…Methods: Medline, Embase, CINAHL Plus, Cochrane, Scopus, Web of science, clinical trials.gov, WHO and EU Clinical Trials Register were searched for RCTs only, on intra-clot fibrinolytics vs standard treatments for ICH and IVH. …”
Get full text

Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry by Cecilia Bonolo de Campos, Chantal E. McCabe, Laura A. Bruins, Daniel R. O’Brien, Sochilt Brown, Renee C. Tschumper, Cristine Allmer, Yuan Xiao Zhu, Kari G. Rabe, Sameer A. Parikh, Neil E. Kay, Huihuang Yan, James R. Cerhan, John N. Allan, Richard R. Furman, J. Brice Weinberg, Danielle M. Brander, Diane F. Jelinek, Marta Chesi, Susan L. Slager, Esteban Braggio

Get full text

CAR T-cell detection scoping review: an essential biomarker in critical need of standardization by Naomi Taylor, Nirali N Shah, David P Turicek, Victoria M Giordani, Josquin Moraly

“…To evaluate whether subsequent manuscripts from a trial resolved these issues, we analyzed all subsequent manuscripts reporting on the 21 clinical trials, recording all expansion and persistence data. …”
Get full text

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination... by Abhishek Abhishek, Jonathan A Cook, Helen M Parry, Anne Francis, Lelia Duley, Vicki S Barber, Paul Moss, Nicholas Peckham

Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

“…This trial was registered at ClinicalTrials.gov (NCT04396457) and the Japan Registry of Clinical Trials (jRCTs041200012).…”
Get full text

Control of atropoisomerism: an access to valuable compounds by Choppin, Sabine, Wencel-Delord, Joanna, Colobert, Françoise

“…Atropoisomerism is well-known in biaryls, however this phenomenon is encountered in many pharmaceutically relevant compounds such as heterobiaryl, diarylamines, benzamides and anilides.Currently four FDA-approved drugs are atropostable and many others are in clinical trials. It is also important to note that almost 30% of recent FDA-approved small molecules are “proatropisomeric” and interact with a target in a specific chiral conformation.Given this vivid interest in C–C but also C–N atropisomerically stable compounds, this account will detail the new atropoisomeric strategies we developed and their applications in the synthesis of relevant molecules and ligands.…”
Get full text

Intestinal microbiome as effective regulator of enteral and central nervous system activity by V. T. Ivashkin, K. V. Ivashkin

“…Accumulated data change the current concept on human microbiome and its potential, however further clinical trials required.…”
Get full text

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis by D. V. Garbuzenko

“…Given a lack of approved antifibrotic therapies in NASH, several drugs have nevertheless demonstrated an adequate efficacy and safety in phase 3 clinical trials, also in compensated cirrhosis, which allows their practical validation in phase 4.Conclusion. …”
Get full text

Understanding cancer predisposition in Singapore: what’s next by Jianbang Chiang, Tarryn Shaw, Joanne Ngeow

“…These include the potential for finding unexpected germline variants through somatic tumour testing, optimal risk management of patients with hereditary conditions involving moderate-penetrance genes, role of polygenic risk score in an under-represented Asian population, management of variants of uncertain significance, clinical trials in patients with germline pathogenic variants and technology in genetic counselling. …”
Get full text

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management by Muhammad Mazhar Azam, Sameen Mukhtar, Muhammad Haris, Fatima Laique, Suhaina Amir, Mubashir Mohiuddin, Bibek Giri

“…This mechanism effectively reduces fibrosis markers, improves liver enzyme levels, and minimizes liver fat buildup. Clinical trials have shown that resmetirom has a favorable safety profile, with manageable side effects like diarrhea and nausea. …”
Get full text